The SMeO 2025 Congress, organized by the Mexican Society of Oncology, was a four-day scientific meeting that brought together national and international specialists to share knowledge on the latest advances, innovations, and best practices in cancer care.
The program featured specialized modules such as radio-oncology, thoracic oncology, and sarcomas, along with panels, debates, and sessions highlighting new therapies and interventions. In addition, the event included a commercial exhibition area where laboratories and institutions presented their work and innovations.
Maite Bourlon, Associate Professor and Head of the Urologic Oncology Clinic at the National Institute of Medical Sciences and Nutrition Salvador Zubirán, and Petros Grivas, Clinical Director of the GU Cancer Program at the University of Washington, shared some insights from the event:
SMeO 2025 with the great experts
“Metastatic urothelial carcinoma!!
With the great experts Petros Grivas, Brian Rini, and Rodrigo Sanchez Roger.
- Javelin 100-100 mg maintenance
- CheckMate 901 cisplatin eligible
- EV + Pembro broad criteria (OS 33 vs 15 months)
- How to treat post-EV + Pembro.”
Happy to represent Fred Hutch Cancer Center on a global level
“Great meeting with excellent speakers, questions, and discussion, happy to represent Fred Hutch Cancer Center on a global level! Need to practice my Spanish!”
“Insightful talk by Brian Rini on 1L mRCC! Ongoing debate TKI/IO vs IO/IO, sarcomatoid seems the best predictive biomarker, favoring IO; KIM1 seems highly prognostic in the adjuvant setting, is it also predictive? OPTIC trial seems interesting!”
Paola Valdez’s recognition during the SMeO 2025
“Congratulations to Paola Valdez for first place in the Mexican Council of Oncology. Recognition during the SMeO 2025.
A thousand congratulations!!! We are proud to have you in the Comprehensive Care Clinic for Genitourinary Tumors.”
“GU Tumor Module at SMeO 2025.
- Kidney, bladder, prostate, testicular, and penile cancer.
- New kidney and bladder treatment
- Radiotherapy, relapse, Biochemistry
- Radioligands, iPARPs, and hormone
- New Penile Cancer IO.”
“Magnificent talk from Andrey Soares at SMeO 2025.
1st line mHSPC duplet vs triplet
- De novo vs recurrent
- Value of PSMA-PET
- Which is the Best ARPi
- Drug interactions and side effects
- iPAPs new kid in the block.”
Rodrigo Sanchez Roger presenting at SMeO 2025
“Biochemical relapse prostate cancer Rodrigo Sanchez Roger presenting at SMeO 2025.
- RT of underutilized salvage
- What we’re going to irradiate: bed, gl!
- Hormonal tx time: 6 vs 24 m
- EMBARK study: ADT vs Enza vs Enza + ADT.”
Talking about prostate cancer and radiopharmaceuticals
“At SMeO2025 with UroTeragLATAM
Talking about prostate cancer and radiopharmaceuticals Lu177-PSMA
- Benefit in OS in mCRPC
- Necessary multidisciplinary approach
- Management of toxicities
- Improving outcomes.”
Fantastic to present at the awesome SMeO 2025
“Fantastic to present at the awesome SMeO2025 meeting co-organized by brilliant Maite Bourlon in Mexico! A huge number of participants and stellar speakers. Attending with Brian Rini, Uromigos, and Rodrigo Sanchez Roger.
Honored to represent Fred Hutch Cancer Center as we launch our international program!”
You can find more posts from SMeO 2025 on OncoDaily.